MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,429,681 shares of the company's stock after selling 345,587 shares during the quarter. Vanguard Group Inc. owned 5.13% of MaxCyte worth $22,587,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. River Global Investors LLP boosted its holdings in shares of MaxCyte by 57.7% in the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company's stock valued at $13,494,000 after purchasing an additional 1,190,630 shares during the last quarter. Royce & Associates LP raised its position in shares of MaxCyte by 146.9% in the 4th quarter. Royce & Associates LP now owns 799,873 shares of the company's stock worth $3,327,000 after buying an additional 475,949 shares during the period. Rice Hall James & Associates LLC acquired a new position in MaxCyte in the fourth quarter valued at $1,098,000. Gagnon Securities LLC grew its position in MaxCyte by 234.1% during the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company's stock valued at $821,000 after acquiring an additional 138,257 shares during the period. Finally, Barclays PLC increased its stake in MaxCyte by 329.3% during the third quarter. Barclays PLC now owns 165,765 shares of the company's stock worth $645,000 after acquiring an additional 127,156 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company's stock.

Analyst Upgrades and Downgrades

MXCT has been the topic of several research analyst reports. Stifel Nicolaus reduced their price objective on MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the company a "buy" rating in a research report on Wednesday, March 12th.

MaxCyte Trading Up 2.4 %

NASDAQ:MXCT traded up $0.06 during mid-day trading on Friday, hitting $2.61. The company had a trading volume of 472,309 shares, compared to its average volume of 530,875. MaxCyte, Inc. has a 1 year low of $2.21 and a 1 year high of $5.26. The business has a fifty day simple moving average of $3.19 and a 200-day simple moving average of $3.74. The firm has a market capitalization of $277.48 million, a price-to-earnings ratio of -7.68 and a beta of 1.39.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.